NPPA cuts price of diabetic drug glipizide, hikes rates of 4 other bulk drugs
The National Pharmaceutical Pricing Authority (NPPA) has brought down the prices of anti-diabetic bulk drug glipizide considerably, increased the prices of four other bulk drugs, and revised the prices of 92 formulations.
The National Pharmaceutical Pricing Authority (NPPA) has brought down the prices of anti-diabetic bulk drug glipizide considerably, increased the prices of four other bulk drugs, and revised the prices of 92 formulations.
The NPPA cut down the price of glipizide from Rs.26,114 to Rs.15,946 per kg, in a measure that would ease the burden of chronic patients taking the oral rapid- and short-acting anti-diabetic drug. A number of multinational and generic companies manufacture and market this drug. Earlier the price was fixed on April 2009.
The notification by the NPPA, dated November 16, however increased the prices of ibuprofen, rifampicin, iodochlorohydroxyquinoline (ICHQ) and metronidazole with its derivatives. The price of popular pain-killer ibuprofen went up from Rs.498 to Rs.527 per kg. It was revised earlier in September, 2011.
Likewise, the price of rifampicin was hiked to Rs.4,485 per kg from Rs.4,111, revised also in September 2011. The new price of ICHQ is Rs.1,526 per kg, against the existing price of Rs.1,158, fixed in September 2011, said the price regulator.
The price of metronidazole was also increased from Rs.514 to Rs.588 per kg while its derivative metronidazole benzoate became expensive from Rs.450 to Rs.525 per kg. The prices of both the bulk drugs were fixed earlier in July 2011.
The agency also revised the prices of 92 formulations. The packs included those of dexamethasone with combination, gentamycin with combination, multivitamin, human insulin, pred forte, madopar, vitalux plus, apidra/lantus, and monocomponent human insulin.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...